Antimicrobial resistance (AMR) is a global problem but information about the 24 prevalence and mechanisms of resistance in sub-Saharan Africa are lacking. We 25 determined the percentage of drug resistant isolates and resistance mechanisms in 307 26
INTRODUCTION 38
Nigeria and other sub-Saharan African countries face an increasing number of 39 healthcare associated infections caused by multi-drug resistant (MDR) Gram-negative 40 bacteria [1, 2] . Pathogenic species have evolved resistance to multiple antimicrobial 41 agents including the mainstays of treatment [3, 4] . This is of particular concern as there 42 are few new antibiotics in development with activity against Gram-negative bacteria [5] . 43
Whilst Gram-negative bacteria are often intrinsically more resistant to many antibiotics 44 than Gram-positive species, drug resistance to the most clinically important antibiotics 45 is largely mediated by genes which are transmitted on plasmids that can readily spread 46 through bacterial populations [6] . Species belonging to the Enterobacteriaceae family 47 are the most commonly isolated MDR bacteria causing healthcare associated infections 48 globally including in sub-Saharan Africa [7] . These bacteria include extended-spectrum 49 β-lactamase (ESBL) producing K. pneumoniae and E. coli which are associated with 50 METHODS 86
Sample sites and bacterial isolates 87
The majority of the Nigerian population is found in the southwest of the country; this is 88 also where major transportation hubs are located. Gram negative bacterial isolates for 89 this study were recovered from patients admitted to three large teaching hospitals 90 located in three states of south western Nigeria from a range of clinical specimens with 91 invasive and colonized infections ( In addition, isolates from stool samples sent for routine examination from patients but 98 without infection were also collected. Isolates were non-duplicate and unbiased (i.e. no 99 selective criteria beyond being a Gram negative bacterial species were applied) and 100 were randomly collected from the hospital laboratories in 2011 and 2013. A total of 306 101 were determined by the disk diffusion method on Mueller-Hinton agar using antibiotic 110 disks from Oxoid Ltd. (Basingstoke, UK) according to the recommendations of 111 EUCAST and interpreted according to EUCAST breakpoints[17] . All susceptibility 112 testing experiments included the control organisms E. coli NCTC 10418 and P. 113 aeruginosa NCTC 10662. 114 Identification of carbapenemase production 115
The Enterobacteriaceae isolates were tested for production of a carbapenemase using 116 the disc based 'Carbapenemase detection set' from Mast Group (Bootle, UK) and 117 interpreted using the 'carbapenemase detection set calculator' tool as per the 118 manufacturers guidelines. 119
Identification of known carbapenemase genes 120
PCR and sequencing were used to identify genes encoding various known beta-121 lactamases (including carbapenemases, NDM, VIM, KPC and GES). Primers used are 122 shown in Table S1 having previously extracted DNA by crude boiling method. 123
RAPD PCR 124
A random amplified polymorphic DNA typing approach was used for each species as a 125 rapid and inexpensive way to assess the diversity of strains within each population. 126 sequencing was used to generate high-quality 250 bp reads. Assembly used Velvet [18] 134 and contigs were re-ordered against relevant reference genomes using MAUVE [19] . 135
Assemblies were annotated using RAST (http://rast.nmpdr.org/rast.cgi). Assemblies 136 were used to search for plasmid content and to determine MLST types using the 137 'PlasmidFinder' and 'MLST' tools hosted at the Centre for Genomic Epidemiology 138 The percentage of the entire collection of 306 isolates that were resistant to 150 fluoroquinolones, third generation cephalosporins and carbapenems being 78.1%, 151 92.2% and 52.3%, respectively (Tables 2 and 3 ). This pattern of high numbers of 152 clinical isolates being resistant to these classes of drug was very similar in all three 153 study sites (fluoroquinolone resistance was seen in 75 -83% of isolates, cephalosporin 154 resistance in 90 -100% of isolates and carbapenem resistance in 50 -55% of isolates). 155
Of concern was the observation that the percentage of isolates from stool of uninfected 156 patients, i.e. those being carried as commensal bacteria that were resistant to third 157 generation cephalosporins (100%) and carbapenems (69.1%) was higher than in isolates 158 from patients being treated for an infection. This suggests that extremely high numbers 159
of antibiotic resistant bacteria are prevalent in the community and that multidrug 160 resistance is not restricted to isolates found in the hospital environment. 161
When stratified by species, E. coli were most commonly resistant to third generation 162 cephalosporins (93.7%) and carbapenems (59.4%), followed by Pseudomonas species 163 (where 91.7% of isolates were resistant to third generation cephalosporins and 51.7% of 164 isolates were resistant to carbapenems) (Tables 2, 3 and 4). Of the 307 isolates, no 165 species had 50% or more of isolates which were sensitive to all three classes of 166 antibiotic. The isolates of Proteus (n=24) were least likely to be carbapenem resistant; 167 nonetheless 48% of isolates were resistant to this class of drug. 168
The isolates in this study were collected in two different years, the percent of 169 fluoroquinolone resistant isolates in 2011 and 2013 was very similar. However, between 170 the two years the percentage of isolates resistant to cephalosporins fell from 97% to 87% and the percentage of carbapenem resistant isolates fell from 59% to 43% (Table  172 1). 173
Typing of isolates 174
RAPD PCR was used to type 54 of 306 isolates representing 18 each of E. coli, K. 175 pneumoniae and P. aeruginosa. A wide variety of strains were present for each species 176 with only a small number of repeated patterns observed e.g. Figure 2 where 13 RAPD 177 patterns were identified from 18 isolates of E. coli demonstrating a lack of dominance 178 by specific clones. 179
Carbapenemase production and identification of carbapenemase genes 180
As there was a high prevalence of carbapenem resistance in the isolates, the E. coli and 181
Klebsiella strains were tested for production of carbapenemases using the 182 'carbapenemase detection set' from Mast Group (Bootle, UK). Only 6% of all isolates 183 produced a carbapenemase (7% of Klebsiella and 10% of E. coli). Specific 184 carbapenemase genes were amplified by PCR and genes verified by DNA sequencing 185 alleles for all 306 isolates. In agreement with the phenotypic testing, only 19 of the 306 186 isolates (6.2%) carried a known carbapenemase gene. The PCR revealed the presence of 187 variants of VIM (n=9), GES (n=10) and NDM (n=2) families. These genes were 188 detected in K. pneumoniae (n=6), E. coli (n=4) and P. aeruginosa (n=9) isolates. Two 189 isolates carried two carbapenemase genes (NDM and VIM and GES and VIM). The 190 KPC, IMP or OXA-48 genes were not detected in any isolate. 191
As 51.3% (157 isolates) of the 306 isolates were resistant to carbapenems but most did 192 not appear to produce a known carbapenemase the presence of other known resistance 193 mechanisms was investigated. The CTX-M genes have been shown to be very common 194 and important in Gram negative isolates among other extended-spectrum β-lactamases around the world, we therefore used primers specific for each of the CTX-M sub-groups 196 were used to detect these genes. Of the 218 E. coli and K. pneumoniae isolates, 79.4% 197 (173) contained a CTX-M allele; DNA sequencing of a random selection of 40 isolates 198 revealed all to be CTX-M-15. None of these isolates demonstrated de-repression of 199 efflux but all showed either complete loss or reduced production of outer membrane 200 porins (data not shown). 201
Characterisation of antibiotic resistance mechanisms and strain types in 202 representative isolates 203
To investigate the molecular basis of drug resistance ten isolates were chosen for whole 204 genome sequencing. These included representative isolates of the most common species 205 and resistance phenotypes present in the collection. The ten isolates included two K. 206 pneumoniae, two E. coli, three P. aeruginosa, two P. mirabilis and one P. rettgeri 207 isolate ( Table 4 ). The choice of isolate was informed by susceptibility testing, year of 208 isolation, site of isolation (both geographical and specimen type) and by results of 209 random amplified polymorphic DNA (RAPD) typing. The sequencing identified some 210 globally established strain types in circulation in Nigeria, notably K. pneumoniae ST11 211 and P. aeruginosa ST224. 212
Both the K. pneumoniae isolates belonged to ST11 and were from urine of different 213 patients in 2011 from UCH. Both genome assemblies were essentially identical and 214 both carried NDM-1 and CTX-M-15 (Table 4 ). In addition, both isolates also carried 215
OXA-1 and SHV-11. Interestingly, there was direct evidence for the mobility of the 216 NDM-1 gene in this strain. Whilst the gene encoding NDM-1 was detected by PCR 217 using a boiled colony preparation as a template in both isolates (U52 and U37), in both 218 genome assemblies created after sequencing isolated DNA preparations, it was only initially seen in the genome assembly for U52. Analysis of the genetic location of this 220 gene showed it to be present in a context like that seen by others previously, in an 221 operon with bleMBL and associated with trpF, dsbC and cutA (Figure 3 ). In isolate U37 222 this region was absent and no sequence reads mapped against the U52 reference (Figure 223 S1) demonstrating likely mobility of this whole region as has been suggested previously 224 [24] . Both IncFIB and FII plasmid replicons were present in both strains supporting a 225 plasmidic context for blaNDM-1 (Figure 3 ). In addition to the beta-lactamase genes, 226 both isolates also carried trimethoprim (dfrA12), macrolide (mphA) aminoglycoside 227 (rmtF) chloramphenicol (cat) and sulphonamide (sul1) resistance genes. Consistent with 228 fluoroquinolone resistance, mutations in gyrA were seen, 229
One of the P. aeruginosa belonged to ST244 and carried the mutant PDC-1 AmpC 230 enzyme as well as genes that contribute to resistance to chloramphenicol (cmx, catB7), 231 aminoglycosides (aph(3")-I1, aph(6)-Id) and fosfomycin (fosA). The other two isolates 232 were both members of ST233 and both carried PDC-3. These latter two isolates also 233 carried VIM-2 and OXA-33, were of the same MLST type and both isolated from 234 OOUTH although isolated two years apart. Reads from the F46 strain carrying VIM-2 235 were assembled using both Velvet and SPAdes (using the plasmidSPAdes option); both 236 resulted in assemblies with the VIM-2 gene present on a contig of ~7000bp. When this 237 sequence was compared with known sequences in Genbank using the BLAST algorithm 238 a perfect match for an integron carrying VIM-2 was found (accession number 239 KT768111.1). Figure 3 shows a plasmid network reconstruction and the genetic context 240 of the VIM-2 genes in these two isolates. 241
The two E. coli strains sequenced belonged to ST226 and ST156. Neither carried known 242 carbapenemase genes although both had multiple mutations within ampD suggesting de-repression of the chromosomal ampC gene. Both strains also carried TEM-1 and various 244 other mobile resistance genes including genes conferring aminoglycoside resistance 245 (aph(6)-Id, aph(3")-I1). An IncFII plasmid replicon was present in isolate S46 (the 246 ST226 isolate). 247
Two P. mirabilis strains were sequenced, isolate F10 carried two CMY genes; CMY-41 248 reported once previously in a Citrobacter freundii isolated from food in Egypt [25] and 249 CMY-31 previously reported in Klebsiella and Salmonella[26. 27] . A Q1 plasmid 250 replicon was present in F10. This isolate also carried two separate aminoglycoside 251 resistance genes (aadA5, aph(3")-I1), as well as chloramphenicol (catI), sulphonamide 252 (sul1) and plasmidic quinolone resistance genes (qnrA1). P. mirabilis isolate F56 was 253 found to carry a novel CMY enzyme with a single substitution (of glutamic acid for 254 aspartic acid at codon 144) distinguishing this protein from CMY-48 isolated from C. 255 freundii. Isolate F56 also carried a chloramphenicol acetyltansferase gene (catI) and 256 three aminoglycoside resistance genes (aadA5, aph(3")-I1 and aph(6)-Id). 257
The Providencia isolate (S39) sequenced carried an SRT-2 AmpC beta-lactamase 258 variant; this has previously been described in Serratia marcescens [28] . No other beta-259 lactamase genes or plasmid replicons were detected in this isolate. 260
DISCUSSION 262
This study suggests that there is a very high prevalence of antibiotic resistance in 263
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